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Abstract
The biggest challenge in prostate cancer treatment is to understand the signaling mecha-
nisms controlling disease progression. In this context, microRNAs assume huge impor-
tance and have recently become an attractive area of research. MicroRNAs are naturally 
occurring, single-stranded, small non-coding RNAs of 19–25 nucleotides that regulate 
gene expression. MicroRNAs function as oncogenes or tumor-suppressor genes, and 
their deregulation is a common feature of human cancers including prostate cancer. 
Among deregulated microRNAs in prostate cancer, some microRNAs are directly under 
androgen receptor signaling control and function as the effectors of androgen signaling. 
Recent findings have shown that apoptosis antagonizing transcription factor (AATF) gene 
encodes a microRNA designated as miR-2909 that plays an important role in prostate 
cancer progression. miR-2909 is identified as an androgen-regulated microRNA acting as 
a novel effector of androgen/androgen receptor signaling. It enhances the proliferation 
potential of prostate cancer cells and assists in prostate cancer survival under reduced 
androgen levels by maintaining a positive feedback loop with AR. miR-2909 exerts its 
oncogenic effects via multiple mechanisms including attenuation of tumor-suppressive  
effects of TGFβ signaling by directly targeting TGFBR2 and via STAT1 pathway and 
upregulation of ISGylation pathway through SOCS3/STAT1 pathway.
Keywords: prostate cancer, hormone-sensitive, castration-resistant, androgen receptor, 
TGFβ, TGFBR2, ISG15, SOCS3, STAT1
1. Introduction
Cancer is one of the leading causes of deaths at the global level accounting for 8.2 million 
deaths in 2012 [1]. Among males, prostate gland is one of the five leading sites of cancer 
accounting for approximately 15% of cancers in men, and the incidence is expected to rise 
steeply by around 19% in the coming years [2, 3]. Prostate cancer (PCa) causes substantial 
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clinical, social and economical burden in both the developing and developed world. The pros-
tate specific antigen (PSA), a protein mainly secreted by prostate cells, is a blood-based marker 
routinely used for early-stage PCa detection as well as to monitor recurrence of PCa after ini-
tial treatment [4]. Even though PSA is a valuable tool, it lacks specificity and is therefore not 
considered an optimal biomarker [5]. Thus, additional novel biomarkers are needed which 
can help to predict the exact level of disease aggressiveness, assist in clinical decision about 
the choice of treatment and aid in establishing more persuasive treatment for the advanced 
PCa. Prostate tumors are reported to display novel recurrent chromosomal translocations and 
aberrant expressions of certain microRNAs (miRNAs) which can be helpful for elucidating 
PCa biology and explored for better disease management [6]. Identification of dysregulated 
genes or miRNAs in PCa cannot only be promising in terms of diagnostics and therapeutics 
but can provide clues relevant to disease etiology and progression. miRNAs are small non-
coding RNAs that finely regulate gene expression in cells. Alterations in miRNA expression 
have been reported to be associated with PCa development and are currently being thor-
oughly investigated as PCa biomarkers. Several miRNAs showing high expression levels in 
PCa tissues are reported as suitable diagnostic or prognostic markers [6]. Among deregulated 
miRNAs in PCa, some miRNAs are directly under androgen receptor (AR) signaling control 
and function as the effectors of androgen signaling [6]. Recent findings have shown apopto-
sis antagonizing transcription factor (AATF) gene encodes a miRNA designated as miR-2909 
that plays an important role in immunity and cancer progression [7, 8]. AATF is known as 
co-activator of AR through its interaction via LXXLL motifs and therefore enhances the AR 
mediated transcription. AR signaling has a critical role in the development of normal prostate 
by triggering various events that promote epithelial cell growth, arrest and differentiation [9]. 
However, this pathway is modified/deregulated to promote cell survival and proliferation in 
PCa [10]. Keeping in view the critical role played by AR signaling in normal prostate and PCa 
development, human AATF genome, that holds AATF gene and its encoded miR-2909 within 
its fold, assumes huge importance. Exploring its role in PCa, miR-2909 was identified as an 
androgen-regulated miRNA acting as a novel mediator of androgen/androgen receptor sig-
naling and exerting its oncogenic effects through multiple pathways. This chapter addresses 
the role played by miR-2909 in the progression of PCa and the potential signaling pathways 
through which it operates. The purpose of this chapter is mainly to bring into limelight the 
role played by one of the less known miRNAs to the readers which when combined with 
another set of miRNAs or specifically AR-regulated miRNAs could be exploited for thera-
peutic and diagnostic purposes, though further studies are demanded to obtain more definite 
conclusions.
2. Prostate gland structure and PCa types
Prostate is a compound tubuloalveolar exocrine gland that plays a vital role in the reproductive 
process by secreting a part of the seminal fluid. The average size of the prostate is about a size 
of a large walnut that is located close to the rectum, below the bladder at the base of the penis. 
The prostatic epithelium is composed of two major cell types: stromal cells and  epithelial cells. 
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There are five types of cells present in prostate epithelium including stem cells, basal epithelial 
cells, transit-amplifying cells, neuroendocrine cells and secretory epithelial cells.
The stromal compartment, which normally serves as structural support, mainly consists of 
connective tissue, smooth muscle cells and fibroblasts. The gland can be divided into three 
glandular zones: the transition zone (TZ), the central zone (CZ) and the peripheral zone (PZ). 
The TZ consists of two lobes, accounting for 5% prostatic volume, whereas CZ is located out-
side the TZ and accounts for about 25% prostatic volume. Outside the CZ is the PZ which con-
stitutes about 70% of the total prostatic volume. Most of the benign hyperplasias and 10–20% 
tumors arise in TZ whereas 70–75% of the prostate tumors arise in PZ. Acinar prostate carci-
noma is the most common histological form whereas other subtypes only account for 5–10% 
of histological forms and include ductal adenocarcinoma, atrophic carcinoma, pseudo-hyper-
plastic carcinoma, foamy gland carcinoma, mucinous carcinoma, signet-ring carcinoma, small 
cell carcinoma, sarcomatoid carcinoma, urothelial carcinoma and squamous cell carcinoma.
3. MiRNAs
miRNAs are naturally occurring 18–24 nucleotides-long non-coding RNA molecules that reg-
ulate the expression of a large number of genes posttranscriptionally either through mRNA 
degradation or inhibition of translation [11]. miRNAs play an important role in a wide range 
of biological processes including cell proliferation, differentiation, development and apop-
tosis [12]. To date, approximately 2000 human miRNAs have been discovered and believed 
to regulate about 30% of human genes. miRNAs are known to regulate genes through three 
different mechanisms including triggering an endonucleolytic cleavage of mRNA, promot-
ing translational repression or through accelerating the deadenylation of mRNA [11]. The 
endonucleolytic cleavage of target mRNAs is usually possible if the miRNA sequence is com-
pletely complementary to the target mRNA sequence although some mismatches could occur. 
However, translational repression occurs if there is a non-perfect match between the two 
sequences. Nucleotides 2–7 from the 5’ end of the miRNA, called seed sequence, are essential 
to the binding of the miRNA to the target mRNA perfectly and all the other nucleotides of the 
miRNA can bind imperfectly. Though majority of data has focused on miRNAs that act via 
canonical pathway, there are no mechanistic requirements that restrict miRNA action to only 
3ˈuntranslated region (UTR). miRNAs have also been reported to regulate mRNA expression 
by targeting 5ˈUTR and open reading frame (ORF) binding sites. Moreover, various studies 
have reported miRNAs that directly bind to DNA and influence gene expression and some 
miRNAs are reported to even activate, rather than inhibit gene expression [13]. Altogether, 
these findings highlight the complexity of gene regulation by the miRNAs.
Lot of miRNAs are located in distinct regions far from protein-coding genes and expressed 
independently from their own promoters. However, 40% of miRNAs are located in introns of 
protein-coding genes and are under the control of same promoter and co-expressed with the 
host gene. Likewise, various miRNAs are located close to each other within 10 kb in the form 
of clusters. miRNAs are normally transcribed as monocistronic by polymerase II whereas 
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clustered miRNAs are transcribed as polycistronic RNAs. The transcribed sequences are a 
few hundred to a few thousand nucleotides in length and are termed as preliminary miRNAs 
(pri-miRNAs). Pri-miRNAs harbor a polyadenyl-tail and have a 5ˈ7-methylguanylate cap (95) 
at the 5’ end. The pri-miRNA synthesized is cleaved by the nuclear microprocessor complex 
formed by Drosha, a member of the RNase III family of enzymes, and the DiGeorge 21 critical 
region 8 proteins. If the seed sequence of miRNA and its target mRNA are highly complemen-
tary, mRNA degradation is induced via the RNAse III catalytic domain of the AGO proteins, 
which is followed by the degradation by exonuclease XRN1, the exosome and SKI complex. If 
the miRNA and mRNA are partially complementary, mRNA degradation is followed through 
different pathways. The poly(A) tail of the mRNA is deadenylated followed by degradation 
of the mRNA from the 3’ end by the cytoplasmic exonucleases degradation mechanism or by 
removal of 5’cap via decapping complex proteins (DCP1 and DCP2) and CAF1-CCR4-NOT 
complexes and then degradation of the mRNA by XRN1 from 5’ to 3’ end [11].
4. MiRNAs in PCa
As miRNAs have been associated with various important physiological processes like devel-
opment, differentiation, apoptosis and cell cycle regulation, thus aberrant miRNA expression 
can result in various pathological states, including cancer [14]. Various studies have shown 
that different miRNAs and their targets are aberrantly expressed in neoplastic PCa tissues 
compared to the normal ones, providing a significant insight into altered cellular growth, 
invasion and metastatic potential of PCa cells [6, 15]. These miRNAs appear to have important 
and unique roles with respect to apoptosis resistance, cell proliferation, epithelial-to-mesen-
chymal transition, invasion, metastasis and development of androgen independence. These 
differentially expressed miRNAs function as either oncogenes or tumor suppressor genes with 
oncogenic being upregulated and tumor suppressors being downregulated. Various miRNA 
expression profiling analytical studies have shown many miRNAs downregulated in PCa 
wherein their elevated levels are indicators of good prognosis [6, 15]. On the contrary, other 
miRNAs are promoters of carcinogenesis and their expression levels are elevated in advanced 
stages of some cancers, which clearly suggests these miRNAs as attractive targets for therapy 
[6, 15]. Although a good number of miRNAs are reported as being differentially expressed in 
PCa, which in turn leads to altered expression and activity of their targets, the understanding 
of the functional importance of only several miRNAs has been molecularly exploited. Such 
studies have established an intimate relationship between PCa and miRNAs with emerging 
data clearly suggesting miRNAs a very promising field in terms of therapeutics, although 
further in-depth mechanistic studies and a better understanding of the key events are desired.
5. miR-2909
miR-2909, previously known as Che-1 and encoded by AATF gene, is known to regulate cru-
cial genes involved in host immunity, energy metabolism and oncogenic/oncostatic activities 
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[8, 16]. AATF/Che-1 genome has emerged like a master epigenetic switch shown to regulate 
cell cycle progression, checkpoint control and apoptosis [17]. A new dimension was added to 
AATF Genome by a finding that AATF acts as co-activator of AR through its interaction via 
LXXLL motifs and thus enhances the AR mediated transcription. AR signaling has a critical 
role in the development of normal prostate by triggering various events that promote epithe-
lial cell growth, arrest and differentiation [9]. However, this pathway is modified/deregulated 
to promote cell survival and proliferation in PCa [10]. Keeping in view the critical role played 
by AR signaling in normal prostate and PCa development, human AATF genome, holding 
AATF gene and its encoded miR-2909 within its fold, assumes huge importance. Further, vari-
ous studies focused to explore the role of miR-2909 in PCa were conducted and the potential 
signaling pathways through which miR-2909 operates were explored. A new dimensional 
role was added to miR-2909 by various studies that revealed miR-2909 as an androgen-reg-
ulated miRNA acting as a novel mediator of androgen/androgen receptor (AR) signaling. 
miR-2909 enhanced the proliferation potential of PCa cells and assisted in PCa survival under 
reduced androgen levels by maintaining a positive feedback loop with AR. Further, miR-2909 
was shown to exert it oncogenic effects by attenuating the tumor-suppressive effects of trans-
forming growth factor beta (TGFβ) signaling by directly targeting transforming growth factor 
beta receptor 2 (TGFBR2) and via signal transducer and activator of transcription 1 (STAT1) 
pathway and by upregulating ISGylation pathway through SOCS3/STAT1 pathway.
6. miR-2909 and AR signaling
AR signaling plays a critical role in the development of normal prostate [9]. However, this 
pathway is deregulated to promote cancer development and progression in PCa patients. 
miR-2909 is identified as an androgen-induced miRNA that functions as a novel mediator 
of androgen/androgen receptor signaling. Comparison of AR negative, PC3 and AR positive 
LNCaP PCa cell lines has shown a three-fold higher expression of miR-2909 in LNCaP cell 
line. Further, androgens were observed to induce an enhanced expression of miR-2909 and 
androgen-deprivation downregulated miR-2909 expression in androgen-dependent LNCaP 
cells. Moreover, the expression level of miR-2909 also increased proportionately when LNCaP 
cells were treated with different concentrations of DHT ranging from 0.1–15 nM. Moreover, 
this androgen-mediated regulation of miR-2909 was executed through AR signaling. To rule 
out any cross-activation of Estrogen receptor-b (ERb) signaling, it was further shown that 
DHT induced miR-2909 expression was significantly blocked in the presence of AR antago-
nists, strongly indicating the involvement of AR in androgen-mediated regulation of miR-
2909 expression. It was further suggested that a positive feedback loop operates between 
AR and miR-2909 in prostate cells (Figure 1). Ectopic expression of miR-2909 in AR-positive 
LNCaP cells resulted in significant upregulation and inhibition of endogenous miR-2909 sig-
nificantly reduced the AR and PSA expression. It is a well-established fact that the expression 
of AR increases in prostate tumor cells. It could therefore be speculated that the positive feed-
back loop between AR and miR-2909 in prostate tumors could help to maintain a steady level 
of AR in the absence of androgens for further progression and development.
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7. miR-2909 stimulates androgen-dependent and androgen-
independent growth
The functional analysis of miR-2909 in PCa was studied by transfecting miR-2909 into differ-
ent PCa cell lines. Ectopic expression of miR-2909 enhanced the proliferation potential of both 
LNCaP and PC3 cells. The treatment of miR-2909-transfected LNCaP cells with an anti-andro-
gen, bicalutamide significantly inhibited the cell proliferation rate. PCa commonly progresses 
from an androgen-dependent (AD) to an androgen-independent (AI) stage. Evaluating the 
role of miR-2909 in AI conditions, it was observed that miR-2909 overexpression significantly 
stimulated the growth of AD-LNCaP cells cultured in androgen-deprived medium and 
rescued them from androgen-ablated growth arrest. Similarly, anti-miR-2909 significantly 
inhibited the growth of AD LNCaP cells. Moreover, overexpression of miR-2909 significantly 
stimulated the growth of AR negative PC3 cells also.
8. miR-2909 and TGF beta signaling
In PCa, multiple AR mediated growth-regulatory signaling pathways are disrupted, disturb-
ing the equilibrium between proliferation and apoptosis and tipping the balance in favor of 
proliferation. TGFβ signaling represents one of the important pathways AR cross talks with 
[18, 19]. Although various studies have shown that AR signaling blocks the TGFβ-induced 
inhibitory effects, however, exact molecular mechanisms are not known yet [20, 21]. We have 
for the first time reported in our study that miR-2909 acts as one of the central mediators of 
this cross talk [22]. TGFBR2, a critical signaling effector of TGFβ signaling, was shown as 
a novel putative target of miR-2909. TGFBR2 expression was downregulated in miR-2909 
overexpressing PC3 cells and upregulated in anti-miR-2909-treated LNCaP cells. Ectopically 
Figure 1. Feedback loop between androgen receptor and miR-2909.
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expressed miR-2909 decreased the basal phosphorylation of SMAD3, a downstream effector 
of TGFβ signaling and thus abrogating TGFβ-mediated cell growth inhibition and apoptosis 
in PC3 cells. Further, a significant upregulation of p21CIP and downregulation of c-MYC and 
CCND1 expression was observed in TGFβ-treated PC3 cells and miR-2909 overexpression 
abrogated these TGFβ-mediated effects (Figure 2). Thus, these results suggest a novel mecha-
nism of escaping tumor-suppressive effects of TGFβ signaling mediated through downregu-
lation of TGFBR2 by miR-2909 alone or AR/miR-2909 axis which could be a vital mechanism 
for PCa cell survival and progression. Supporting this data, various studies have shown that 
downregulation of TGFBR2 induces malignant transformation while TGFBR2 activation pro-
motes the pro-apoptotic function in vitro as well as in vivo [23, 24]. The significance of TGFβ 
pathway in castrate-resistant prostate cancer is further supported by various studies that have 
reported an association between reduced TGFBR2 expression with higher Gleason score and 
elevated risk of relapse or decreased survival rate after androgen depletion therapy in PCa 
patients [25, 26].
9. miR-2909 and ISGylation
ISG15 is an interferon-induced 165-amino-acid (17 kDa) protein that belongs to a ubiquitin-
like protein superfamily [27]. Like ubiquitin, ISG15 has diverse functions including ISGylation, 
a ubiquitin-like modification process by which ISG15 covalently conjugates to cytoplasmic 
and nuclear proteins through its conserved LRLRGG sequence and alters their functional 
properties [28]. A significant upregulation of all components of ISGylation including ISG15, 
Figure 2. Schematic model summarizing the role of miR-2909 in PCa.
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HERC5, UBE1L and UBE2L6 were observed in miR-2909 over-expressing PC3 cells (Figure 3). 
Further, it was observed that miR-2909 overexpression modulated ISGylation through STAT1 
mediated via negative regulation of SOCS3. A significant upregulation of STAT1 phosphor-
ylation and downregulation of SOCS3 was detected in miR-2909-overexpressing PC3 cells 
whereas miR-2909 plasmid coupled with antagomiR-2909 treatment significantly downregu-
lated phosphorylated STAT1 and upregulated SOCS3 expression [29]. The SOCS3 is a well-
documented inhibitor of JAK/STAT pathway and STAT1 phosphorylation is always reported 
as inversely correlated with SOCS3 expression [30]. A pro-tumorigenic activity mediated by 
miR-2909-induced ISGylation upregulation via STAT1 is supported by various studies report-
ing constitutive STAT1 activation as tumor-promoting in multiple cancer models. A positive 
correlation between increasing STAT1 expression and pro-proliferative gene expression with 
increasing disease progression from benign human papilloma virus-negative and benign 
human papilloma virus-positive, malignant cervical squamous carcinoma cells have been 
reported [31]. A similar kind of correlation between STAT1 with increasing disease progres-
sion from ductal carcinoma in situ to invasive carcinoma in breast cancer biopsies has also 
been reported. Likewise, the STAT1 expression in human breast cancer has been reported to 
be a predictive marker of poor prognosis as well as chemotherapy and radiotherapy resis-
tance [32, 33]. Ectopic expression of miR-2909 in PC3 cells increased their proliferation rate 
and silencing miR-2909-induced or endogenous level of ISGylation process in PCa cells sig-
nificantly reduced the cell proliferation rate. Cell cycle analysis also revealed a significant 
decrease in fraction of cells in S phase, clearly indicating the effect of miR-2909 on cell prolif-
eration could be partly mediated via ISGylation.
In support of these results, interferons have been shown to upregulate AR expression, a mol-
ecule known to play a critical role in PCa development and progression. Similarly, Kiessling 
et al. [34] have shown that UBE1L overexpression, one of the limiting components of ISGylation 
Figure 3. Downregulation of ISGylation through AR/miR-2909 axis in AR-positive LNCaP cells.
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in LNCaP cells, increased AR levels in an ISG15-dependent manner. In breast cancer also, 
ISG15 is reported to stabilize oncogenic K-Ras protein via modifying it through ISGylation by 
inhibiting its targeted degradation via lysosomes [35]. All these observations clearly implicate 
that miR-2909 may very well play an important role in PCa progression through modulating 
ISGylation process.
Moreover, it is well-known that the signaling events triggered by TGF-β are negatively reg-
ulated by STAT1 through SMAD7 [36]. Phosphorylation of STAT1 induces transcription of 
SMAD7, which is a negative regulator for the cascade of SMAD3-mediated TGF-β signaling. 
miR-2909 overexpression significantly upregulated the expression of SMAD7 and decreased 
SMAD3 phosphorylation in PC3 cells (Figure 2). Moreover, the effect was reversed and the 
expression of SMAD3 resumed to normal levels when SMAD7 was inhibited using si-SMAD7. 
TGFβ is known to be a negative growth regulator that plays a critical role in PCa by controlling 
cell proliferation and apoptosis. An expanding body of evidence has indicated dysfunctional 
TGFβ signaling in various malignancies including PCa. Henceforth, all these studies suggest 
modulation of TGF-beta signaling by miR-2909 through multiple mechanisms. As ISGylation is 
known to play a pro-tumorigenic role and is also associated with poor prognosis, thus miR-2909 
could serve as a potential prognostic biomarker for cancer patients. Further, the negative regu-
lation of TGFβ signaling signifies that miR-2909 plays a pro-tumorigenic role by manipulating 
multiple signaling pathways. However, these studies represent the preliminary attempt and 
need to be further extended to human clinical PCa samples where these in vitro studies could 
be validated and the potential role of miR-2909 as a therapeutic biomarker could be established.
10. Urinary-exosomal miR-2909 and PCa
Exosomes are small membrane-bound vesicles of 40–100 nm in diameter found in a broad 
range of biological fluids. They play a critical role in cross talk between tumors and the sur-
rounding environment. Various molecules encapsulated in these vesicles circulating in various 
body fluids are proteins and nucleic acids including mRNA and miRNAs [37, 38]. Various 
studies have reported a change in the content of freely circulating exosomal miRNAs during 
tumorigenesis reflecting the situation in the tumor [38]. Samina et al. [39] studied the relative 
urinary exosomal recruitment levels of two miRNAs, that is, mir-2909 & miR-615-3p in human 
subjects suffering from either bladder cancer or PCa. Urinary exosomes, derived from human 
subjects suffering from PCa, were found to be enriched with miR-2909 compared to those 
derived from either healthy control subjects or benign prostatic hyperplasia (BPH) subjects 
or patients with urinary bladder cancer. In contrast, miR-615-3p was significantly recruited to 
urinary exosomes in subjects suffering from both bladder and PCa compared to those found 
in either healthy-control subjects or disease-control subjects suffering from BPH. Elucidating 
the correlation of urinary exosomal miRNAs with PCa severity, the extent of miR-2909 recruit-
ment to the urinary exosomes showed significant correlation with the severity of PCa based 
on Gleason Score within different subgroups grouped into Hormone-sensitive or Hormone-
insensitive or Hormone-naive groups [39]. Further, in this study, it was reported that the serum 
PSA levels did not correlate with the severity of PCa either in Hormone-sensitive or Hormone-
insensitive subjects. Moreover, no significant  relationship between severity of PCa and age was 
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observed. From this study, it can be implied that urinary-exosomal miR-2909 cannot only help 
to differentiate bladder cancer from PCa but can also help to know the aggressiveness of PCa.
11. Clinical applications
Currently, PSA measurement is the only routinely performed test for the diagnosis of PCa. 
PSA is a coagulase protein secreted by prostate epithelial cells into semen. When the level of 
PSA goes above 4 ng/ml, the subject is asked to go for prostate biopsy for further evaluation. 
However, the PSA testing is non-specific as elevated PSA levels due to BPH, infection and/or 
chronic inflammation may sometimes lead to confounding results leading to over-diagnosis 
and over-treatment for insignificant tumors. Moreover, PSA measurement can also give false 
negative results as sometimes the patients suffering from PCa show a PSA level within nor-
mal range, thus leading to wrong diagnosis. Another important limitation of PSA testing is its 
lack of ability to identify aggressive and lethal forms of PCa. Thus, even though PSA is a valu-
able tool, it lacks specificity and is therefore not considered an optimal biomarker. Therefore, 
novel biomarkers are extremely desired due to the limitations of PSA.
The current research scenario gives compelling reasons to believe that miRNAs could serve 
as potential therapeutic tools in the form of monotherapy or in combination therapy with the 
available medical treatments. miRNAs alone or allied with PSA testing can serve together as 
potential biomarker for the accurate diagnosis of PCa [40, 41]. From the above studies, it can 
be implied that detection and quantification of miR-2909 alone or in combination with other 
miRNAs could serve as a reliable, non-invasive biofluid-based diagnostic test that can help to 
determine the presence and nature of a prostate malignancy as well as its response to treat-
ment. However, it is to be insisted that a good number of investigational studies based on 
larger number of patients are needed to obtain more definite conclusions.
12. Conclusion
Collectively, miR-2909 is an androgen-inducible miRNA that forms a positive loop with AR 
and helps in prostate cancer progression. miR-2909 exerts its oncogenic effects via multiple 
mechanisms including attenuation of tumor-suppressive effects of TGFβ signaling and by 
upregulating ISGylation pathway. Moreover, it can be speculated that the recruitment of miR-
2909 within the urinary exosomes in PCa patients can act as a non-invasive diagnostic marker 
for all the traits of PCa severity.
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